Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-TTM in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
(WorldNews Health)

Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-TTM in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS) - Milestone represents the first patient dosed with Precigen`s transformative non-viral UltraCAR-T therapeutic platform that eliminates ex vivo expansion and reduces manufacturing time to fewer than two days following gene transfer GERMANTOWN, Md., June 26, 2019/PRNewswire / -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients,...